Ticagrelor Versus Clopidogrel in Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 900 participants.

Also called NCT05553613

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 900 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05553613
Other papers using this trial's data
  • TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial CNS drugs, 2025-01 DOI, PubMed 39520630, PMC11695443 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05553613. Randomized; double masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2023-10-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor Versus Clopidogrel in Ischemic Stroke
Intervention (Drug)
Ticagrelor 90 MG Oral Tablet
Intervention (Drug)
Clopidogrel tablet
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct05553613
Content hash
26e6b539f61a9dddcff6694bf4ce1f1738bcc68a33e8a8fedfb3c2d3adaf6f3c